Full text

Turn on search term navigation

© 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Purpose

To evaluate the effectiveness of Kami Guibi‐tang (KGT) in the treatment of mild cognitive impairment (MCI) using magnetic resonance imaging (MRI) on brain metabolites, neurotransmitter, and cerebral blood flow (CBF).

Methods

We randomly allocated a total of 30 MCI patients to a KGT (N = 16) or a placebo (N = 14) group and performed MRI scans before and after 24 weeks of treatment. The participants underwent brain magnetic resonance spectroscopy and MRI scans to obtain brain metabolites using Point‐RESolved Spectroscopy (PRESS) single‐voxel spectroscopy, gamma‐aminobutyric acid (GABA) neurotransmitter using Mescher–Garwood PRESS, and CBF using pseudocontinuous arterial spin labeling sequences using a 3.0 Tesla MRI system. We analyzed metabolite and neurotransmitter levels and CBF using repeated‐measure analysis of variance to evaluate between‐subject group effect, within‐subject treatment condition effect, and interaction of group by condition (group x condition).

Results

The GABA+/creatine (Cr) ratio values were not significantly different between the before and after treatment conditions. The glutamate complex/Cr ratio difference before and after treatment was lower in the KGT group than in the placebo group, but was not statistically significant (p = 0.077). The result of region of interest–based CBF measurement showed that CBF values were significantly lower after treatment at Cluster 2 for the KGT group (p = 0.003) and the placebo group (p = 0.011), at hippocampus for the KGT group (p = 0.004) and the placebo group (p = 0.008), and at the fusiform gyrus for the KGT group (p = 0.002). Furthermore, the absolute CBF difference before and after treatment in the fusiform gyrus was significantly lower in the KGT group than in the placebo group (p = 0.024).

Conclusions

Although a KGT treatment of 24 weeks showed some significant impact on the level of CBF, the Korean version of the mini‐mental state examination score was not significantly different between before and after treatment conditions, indicating that there was no memory function improvement after treatment in amnestic MCI patients. Therefore, further studies should be performed with a relatively larger population and extending the duration of the KGT treatment.

Details

Title
Treatment evaluation of Kami Guibi‐tang on participants with amnestic mild cognitive impairment using magnetic resonance imaging on brain metabolites, gamma‐aminobutyric acid, and cerebral blood flow
Author
Seung‐Yeon Cho 1 ; Kwon, Sharonkyuhee 2 ; Hee‐Yeon Shin 3 ; Ha‐Ri Kim 3 ; Jeong‐Hwa Kim 3 ; Park, Soonchan 4 ; Chang‐Woo Ryu 4 ; Jung‐Mi Park 1 ; Richard A.E. Edden 5 ; Geon‐Ho Jahng 4 

 Stroke and Neurological Disorders Center, Kyung Hee University Hospital at Gangdong, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea 
 Department of Biomedical Engineering, Undergraduate School, College of Electronics and Information, Kyung Hee University, Yongin‐si, Gyeonggi‐do, Republic of Korea 
 Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea 
 Department of Radiology, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Republic of Korea 
 Division of Neuroradiology, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 
Pages
151-164
Section
MEDICAL IMAGING
Publication year
2021
Publication date
Nov 2021
Publisher
John Wiley & Sons, Inc.
e-ISSN
15269914
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2598115173
Copyright
© 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.